Park Medi World LtdNSE:PARKHOSPS
Current view Q4 2026
Buys and builds hospitals at half the usual cost, then fills the beds. Profit up 27%, now debt-free, and future expansion is fully self-funded. A third of beds still empty means room to grow.
Latest exchange filings last 5 · 5 after Q4 2026
- 16 Sep ’26Management will skip Anand Rathi G-200 Summit 2026 on Sept 21; other conference plans unchanged. ↗
- 16 Sep ’26Park Medi World's subsidiary signed 28-year O&M agreement for 300-bed Kanpur hospital; effective by April 1, 2027. ↗
- 8 Sep ’26Park Medicity Prayagraj Limited incorporated on Sept 8, 2026 for 550-bed hospital in Prayagraj, Rs.0.15 crore. ↗
- 5 Sep ’26Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 5 Sep ↗
- 4 Sep ’26Shareholder Meeting / Postal Ballot-Scrutinizer"s Report 4 Sep ↗
Exchange filings, with the company's own one-line summary, read off the same page as the figures. Screener publishes only the most recent few, so this is the last 5 — not everything filed since your note, and a quiet-looking list is not proof of a quiet quarter. A filing is marked new when it is dated after the end of the quarter your note covers. Not scored, and not a judgement — a routine repayment notice and a takeover sit in the same list.
AI concall report · Q4 2026
The full earnings-call read behind this view — what management promised, what they delivered, and the earning trigger.
Growth Q4 2026
| Metric | This year vs lastYoY · vs Q4 2025 | vs the quarter beforeQoQ, sequential · vs Q3 2026 | 3-year yearly average3Y CAGR · compounded | 5-year yearly average5Y CAGR · compounded |
|---|---|---|---|---|
| Sales | ▲ +29.9% | +12.2% | +10.2% | +17.0% |
| Operating profit | ▲ +44.3% | +28.3% | +5.6% | +8.9% |
| EPS | ▲ +40.2% | +40.2% | −25.2% | −40.5% |
| PAT | ▲ +48.1% | +45.3% | — | — |
Tinted rows drive the Tier. Tier = the weaker of YoY Sales and YoY PAT growth. Here the weaker is Sales at +29.9%, which is ≥ 20% → Tier 1.
QoQ is sequential, not a trend. For most Indian companies the March quarter is seasonally the largest, so a June-quarter fall against it is a calendar effect. Only the YoY column feeds the Tier.
Multibagger potential
Poor30/100
⚠ Your own view here is Positive, and the figures are not. The note above is where the reason lives; the score only sees the numbers.
Earnings are shrinking, not growing. Profit per share fell 25% a year over the window measured. Nothing compounds from here until that turns, whatever the price does.
No forward view — earnings are not compounding, so there is nothing to project.
Multiple moved without the earnings — the return sits in sentiment.
How this is calculated
Band capped: earnings are not growing over the measured window.
Growth rate used: -25.2% — the weakest of
EPS / Sales / Op-profit from 3-year EPS CAGR. Latest quarter reads 40%. Price move is a proxy (distance from the 40-week EMA) until ret1y is stored.
How it compares with its rivals Healthcare · 6 of 30 listed
These are the industry's largest names rather than companies of its own size, so the columns are worth reading straight across — a ranking against them would only be restating the size gap.
| Company | Price | P/E | Size | ROCE | Profitlast qtr | Saleslast qtr |
|---|---|---|---|---|---|---|
| Park Medi World | ₹282 | 43.9× | ₹12,176 Cr | 19.5% | +42.3% | +19.3% |
| Apollo Hospitals | ₹8,827 | 60.3× | ₹1.27 L Cr | 17.4% | +34.2% | +20.6% |
| Max Healthcare | ₹1,053 | 68.4× | ₹1.02 L Cr | 14.7% | +4.9% | +16.7% |
| Manipal Health | ₹738 | 109.6× | ₹97,055 Cr | 12.1% | −7.9% | +38.1% |
| Fortis Health. | ₹895 | 63.4× | ₹67,588 Cr | 13.4% | +3.4% | +17.5% |
| Aster DM Quality | ₹764 | 184.5× | ₹66,574 Cr | 11.6% | −46.1% | +21.6% |
Screener's own peer group, from the request already made for the industry P/E. It serves the industry's largest names by market cap, not companies of a similar size, so treat this as context rather than a like-for-like table; this company is always shown. On a phone the price, size and sales columns are dropped rather than pushed off the edge. Not part of the score.
Business quality to Jun 2026
| Are the margins widening? | yes — a little wider than 18 months earlier | operating margin 24% → 26% over 18 months |
|---|---|---|
| Did the profit turn into cash? | more than all of it — reserves released cash too | 96% last year, 109% over three · free cash flow ₹209 cr, positive in 5 of 5 years |
| Is the growth borrowed? | lightly borrowed | ₹364 cr — 0.18× its own equity (was 0.65×) |
| Is it being collected? | customers are paying faster | 129 days to collect, down 32 in a year · cash cycle −2 days |
| Who has been buying? | promoter stake unchanged on record | promoters 82.9% · FIIs 0.8% · DIIs 8.9% |
| What does it earn on its capital? | earns a fair return on its capital | ROCE 19.5% · ROE 16.8% |
Fetched from the filings, not typed — and deliberately not part of the score. These are the questions the score cannot ask: it reads growth, price and trend, so a company can score well while its profit never becomes cash. Weigh these beside the note, not against the number.
Screener's own checklist not mine, not the score
In its favour
- Company has reduced debt.
Against it
- Though the company is reporting repeated profits, it is not paying out dividend
Generated by screener.in from a fixed checklist — not written by me and not an input to the score. It is here as a second machine opinion to weigh against the note; where it disagrees with the view above, the note is the considered one.